Featured Story | | | Friday, July 7, 2017 Daniel O’Connor has resigned as CEO of Advaxis. The cancer immunotherapy biotech has put CBO Tony Lombardo in charge while it searches for a permanent successor to O’Connor. |
|
|
Top Stories Friday, July 7, 2017 Zealand Pharma has become the latest European biotech to file for a Nasdaq IPO. The Sanofi-partnered peptide specialist is seeking about $86 million (€75 million) to take its treatments for insulin shock and short bowel syndrome through clinical trials and up to registration. Friday, July 7, 2017 After three and a half years, Johnson & Johnson is ducking out of a partnership with Capricor Therapeutics focused on the use of stem cells to treat cardiovascular disease. Friday, July 7, 2017 Zebra Medical Vision has teamed up with India’s Teleradiology Solutions to bring its AI-enabled image analysis system to 20 countries in Asia and Africa. The agreement will see Zebra’s medical image analyzing algorithms pushed to up to 150 hospitals around the world. Friday, July 7, 2017 Axonics Modulation Technologies raised $20.5 million in the second closing of its series C financing, which will give the company a boost as it prepares for FDA submission. Thursday, July 6, 2017 In this week's EuroBiotech Report, U.K. Brexit hopes take shape, BioNTech posts cancer vaccine data, GlaxoSmithKline pens an AI pact and more. Friday, July 7, 2017 Celgene is buying Chinese firm Beigene’s PD-1 inhibitor BGB-A317, Fosun's stock slides as rumors about its chairman emerge again, Neopharma is making a series of expansions in Japan and Abu Dhabi, and more. Friday, July 7, 2017 Stada replaced its CEO and CFO as Bain and Cinven prepare for a second buyout bid, ex-Alexion chief David Hallal joined Scholar Rock as chairman, CRISPR-Cas9 player Caribou named a University of Berkeley alumni as CSO. Plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Cardinal Health. | |  | [Webinar] Accelerating Clinical Trials through Adaptive Designs
Thursday, August 3 | 2pm ET / 11am PT
Early-phase adaptive clinical trials help companies accelerate product development by combining multiple clinical objectives into one study to deliver high-quality data and substantial time and cost savings. This interactive webinar will provide the framework for scientifically robust and efficient early-phase clinical drug development. Reserve Your Spot Today! |
| | | Georgia public health head Brenda Fitzgerald has been named as the new leader for the Centers for Disease Control and Prevention. Reuters article RNAi biotech Alnylam Pharmaceuticals and Sanofi Genzyme have started their Atlas phase 3 program for fitusiran, across three separate trials, including for patients with hemophilia A and B. Release | |
|
Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
